Imatinib Is Safe and Effective In Patients with Refractory Chronic Graft Versus Host Disease: Analysis of Two Consecutive Prospective GITMO* Studies.*Gruppo Italiano Trapianto Midollo Osseo
2010; Elsevier BV; Volume: 116; Issue: 21 Linguagem: Inglês
10.1182/blood.v116.21.246.246
ISSN1528-0020
AutoresAttilio Olivieri, Michele Cimminiello, Franco Locatelli, Marco Zecca, Paolo Corradini, Francesca Patriarca, Nicola Mordini, Pasquale Iacopino, Amedea Donelli, Carmine Selleri, Manuela Badiali, Giovanna Lucchini, Guido Gini, Pietro Leoni, Alberto Bosi, Andrea Bacigalupo,
Tópico(s)Myeloproliferative Neoplasms: Diagnosis and Treatment
Referência(s)